PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV

Eli Lilly Just Proved GLP-1 Prices Could Be Lower… Here’s the Chart!

20:28May 2026

Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

According to the video, the speaker of the channel walks through 10 points from Eli Lilly's Q1 2026 earnings call, held April 30, 2026, and translates them for patients. He says he and his wife have paid out of pocket for GLP-1s because their insurance never covered them for obesity. He states the quarter brought $19.8 billion in revenue and profits up 156%. He says this is not medical or financial advice.

Published by DOWNSIZED on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

The central section is a pricing chart from Lilly's slide deck. The speaker says Lilly cut U.S. prices by 7%, prescription volume rose 49%, and U.S. revenue grew 43%. He cites Mounjaro sales rising from $3.8 billion to $8.7 billion and Zepbound from $2.3 billion to $4.2 billion. He argues this shows lower prices and higher profits can occur together. He also reports that 45% of current Zepbound prescriptions and 55% of new ones are self-pay.

Other points include the new FounDAO pill and its slower launch, the Medicare bridge program starting July 1, 2026 with a $50 monthly cap and limits on eligible products, Lilly Employer Connect, international expansion, the Achieve 4 cardiovascular results, retatrutide, the amylin drug lorcaserin tide, and the Zepbound QuickPen. The speaker closes by saying access remains difficult for many patients and encourages viewers to advocate and read program fine print.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:02 The speaker says the FounDAO pill is available but its launch is behind expectations and behind Novo Nordisk's oral Wegovy.
  2. 4:24 He says the Medicare bridge program starts July 1, 2026 with a $50 monthly cap, but only certain patients, drugs and formulations qualify.
  3. 6:39 He says Lilly's own chart shows a 7% U.S. price cut came with 49% more prescriptions and 43% higher U.S. revenue.
  4. 9:44 He reports that 55% of new Zepbound prescriptions in the U.S. are self-pay.
  5. 12:48 He describes Achieve 4 results, including 16% lower cardiovascular risk, and notes the all-cause death finding was not statistically controlled for multiple comparisons.
  6. 13:44 He covers retatrutide, a triple agonist, with the larger TRIUMPH 1 obesity readout expected later in the quarter.

Key moments

Tap one to play from there.

  1. 0:00 Eli Lilly Just Proved GLP-1 Prices Could Be Lower… Here’s th
  2. 1:54 Eli Lilly's Q1 2026 Earnings Call
  3. 2:28 10 Things That Mattered
  4. 2:34 1. The Pill is Real.
  5. 4:24 2. If you are on Medicare, July 1st is your date
  6. 6:40 3. The chart that proves everything we have been saying abou
  7. 9:30 4. If you self-pay for Zepbound, you are now part of the maj
  8. 10:30 5. Ask your employer about Lilly Employer Connect

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Wegovy, Zepbound, Mounjaro and tirzepatide

Questions this video answers

When does the Medicare GLP-1 bridge program start and what does it cost?

According to the video, the CMS bridge program launches July 1, 2026 and runs through December 2027, with out-of-pocket cost capped at $50 a month. The speaker says eligible drugs are Zepbound, Wegovy, and the Zepbound QuickPen only, and patients must meet BMI thresholds and have a qualifying condition.

What did Eli Lilly's chart show about GLP-1 prices and revenue?

The speaker says the chart shows Lilly cut U.S. prices by 7% while prescriptions rose 49% and U.S. revenue grew 43%. He argues this shows prices can come down without hurting the business.

How many Zepbound patients pay cash?

The video states that 45% of current Zepbound prescriptions and 55% of new Zepbound prescriptions in the U.S. are self-pay.

What is retatrutide and when will more data come out?

The speaker describes retatrutide as a triple agonist acting on GLP-1, GIP and glucagon receptors. He says the TRIUMPH 1 obesity trial is expected to report later this quarter, with fuller results at the American Diabetes Association meeting in June.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • GLP-1 patient assistance programs: what Lilly Cares and Novo's PAP actually cover

    Both makers run free-drug programs for people with low income and no insurance or Medicare, but neither covers its weight-loss GLP-1. Novo Nordisk's Patient Assistance Program supplies Ozempic injections free to uninsured patients at or below 200% of the federal poverty level, and lists no Wegovy and no pills. Lilly Cares lists Trulicity as its only GLP-1: no Mounjaro, no Zepbound, no Foundayo. For weight loss, the realistic low-cost routes are the Medicare GLP-1 Bridge at $50 a month and the cash market.

  • Foundayo: the GLP-1 pill where buying direct is the cheap route

    Lilly's oral GLP-1 was approved on 1 April 2026, and it does something no other weight-loss pill does: you take it any time of day, with or without food. The pricing is the surprising part. Lilly self-pay starts at $149 a month, and the one telehealth program on our board selling it, Sesame Care, charges $208 once its membership fee is counted. That reverses the usual arithmetic in this market, and the reason is simple: orforglipron is a new small molecule under patent, so there is no compounded version to undercut it.

  • Does Medicare cover GLP-1s? Ozempic, Wegovy and Zepbound, route by route

    Yes, by two different routes. Medicare drug plans (Part D, including Medicare Advantage plans with drug coverage) cover Ozempic and Mounjaro for type 2 diabetes. For weight loss, the Medicare GLP-1 Bridge covers Wegovy (pen or pill), the Zepbound KwikPen and Foundayo for a $50 monthly copay from 1 July 2026 to 31 December 2027, if you meet CMS's BMI criteria. The catch: the Bridge runs outside Part D, so that $50 never counts toward your deductible or out-of-pocket cap.

Next steps

Wegovy prices

Insurance

Find more like it

Side effectsDose changeWeigh-in and resultsCost and insuranceExercise and strengthHow it worksThe trials

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV